Abstract:Chia-Hung Chen, 1 Chih-Yen Tu, 1 Wei-Chih Chen, 2 Li-Kuo Kuo, 3 Yao-Tung Wang, 4 Pin-Kuei Fu, 5 Shih-Chi Ku, 6 Wen-Feng Fang, 7 Chin-Ming Chen, 8 Chih-Cheng Lai 9 1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; 2 Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 3 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan; 4 Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; 5 Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 6 Division of Chest Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 7 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 8 Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan; 9 Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan Correspondence: Chih-Cheng Lai Email Objective: The aim of this study was to compare the usefulness of cefoperazone-sulbactam and that of piperacillin-tazobactam in the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Methods: This retrospective study included the adult patients receiving cefoperazone-sulbactam or piperacillin-tazobactam against HAP/VAP in nine hospitals in Taiwan from March 1, 2018 to May 30, 2019. Primary outcome was clinical cure rate. Results: A total of 410 patients were enrolled. Among them, 209 patients received cefoperazone-sulbactam and 201 patients received piperacillin-tazobactam. Overall, cefoperazone-sulbactam group had similar distribution of age, sex, or SOFA scores as piperacillin-tazobactam group. However, cefoperazone-sulbactam had higher comorbidity score and disease severity than piperacillin-tazobactam group (Charlson score: 6.5 ± 2.9 vs 5.7 ± 2.7, p < 0.001; APACHE II score: 21.4 ± 6.2 vs 19.3 ± 6.0, p = 0.002). Regarding clinical outcomes, no significant difference in clinical cure and failure rates was observed between cefoperazone-sulbactam and piperacillin-tazobactam group (clinical cure rate: 80.9% vs 80.1% and clinical failure rate: 17.2% vs 18.4%, p = 0.943). Moreover, no significant difference in clinical effectiveness and ineffectiveness rates was observed between cefoperazone-sulbactam and piperacillin-tazobactam group (clinical effective rate: 80.9% vs 80.6% and clinical ineffective rate: 17.7% vs 18.9%, p = 0.711). The all-cause mortality rates of the cefoperazone-sulbactam and piperacillin-tazobactam groups were similar (23.9% vs 20.9%, p = 0.48). After adjustment of Charlson score and APACHE II score, the similarities in these clinical outcomes did not change in overall patients and patients with HAP or VAP. Conclusion: For treating adult patients with nosocomial pneumonia, cefoperazone-sulbactam was as effective as piperacillin-tazobactam. Keywords: cefoperazone-sulbactam, hospital-acquired pneumonia, piperacillin-tazobactam, ventilator-associated pneumonia Hospital-acquired pneumonia (HAP) is the most common type of hospital-acquired infections, 1 , 2 and ventilator-associated pneumonia (VAP) is also a common type of infection in intensive care units (ICUs). 3 Importantly, both HAP and VAP are associated with high morbidity, mortality, and health-care expenditure. 2–4 Although administration of appropriate antibiotics remains the most important treatment for patients with HAP/VAP, 2 , 3 the emergence of antibiotic resistance among causative pathogens—multidrug resistant organisms (MDROs)—has largely limited therapeutic options. Gram-negative bacilli (GNB), such as Pseudomonas aeruginosa and Enterobacteriaceae , play an important role in HAP/VAP, 5–7 and many kinds of antibiotic-resistance mechanism have been detected among these pathogens. 8 , 9 Therefore, a combination of ß-lactam and ß-lactamase inhibitor as a broad-spectrum antibiotic was recommended as one of therapeutic options in the treatment of HAP/VAP. Cefoperazone-sulbactam is one of combinations of ß-lactam and ß-lactamase inh -Abstract Truncated-

Is the fluoroquinolone combination necessary for empirical antibiotic regimen in severe community-acquired pneumonia?

Clinical evaluation on the empirical treatment of community acquired pneumonia

Combination Antibiotic Therapy Versus Monotherapy for Pseudomonas Aeruginosa Bacteraemia: A Meta-Analysis of Retrospective and Prospective Studies

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant <i>Pseudomonas</i> aeruginosa Infection

Biochanin A partially restores the activity of ofloxacin and ciprofloxacin against topoisomerase IV mutation-associated fluoroquinolone-resistant Ureaplasma species.

Efficacy of Caspofungin Combined with Trimethoprim/sulfamethoxazole As First-Line Therapy to Treat Non-Hiv Patients with Severe Pneumocystis Pneumonia.

Meta-analysis of the Effects of Combination Therapies of Β-Lactams and Fluoroquinolones or Macrolides in the Treatment of Community-Acquired Pneumonia.

Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study

Efficacy and Safety of Intravenous Moxifloxacin Versus Cefoperazone with Azithromycin in the Treatment of Community Acquired Pneumonia

Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients

Fluoroquinolones as an alternative treatment for Klebsiella pneumoniae liver abscess and impact on hospital length of stay

Sequential moxifloxacin therapy in hospitalized patients with community-acquired pneumonia

Risk Factors for Community-Onset Pneumonia Caused by Levofloxacin-Nonsusceptible Streptococcus Pneumoniae.

Retrospective Analysis of Fosfomycin Combinational Therapy for Sepsis Caused by Carbapenem-Resistant Klebsiella Pneumoniae.

Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis.

Effect of fluoroquinolone treatment on the diagnosis of pulmonary tuberculosis:clinical analysis of 103 cases of tuberculosis misdiagnosed as community-acquired pneumonia

Treatment of Community-Onset Pneumonia in Neutropenic Cancer Patients: Β-Lactam Monotherapy Versus Combination Antibiotic Regimens

Evaluation on Efficacy of Initial Empirical Antimicrobial Therapy for Patients with Community Acquired Pneumonia in Emergency Ward

Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

The comparison of outcomes in community-acquired pneumonia treated azithromycin or doxycycline in combination with beta-lactams: A cohort study